Medicalgorithmics SA

  • Market Cap: Small Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: PLMDCLG00015
PLN
32.15
7.1 (28.34%)
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryPrice Point
High/Low

1Day

52 Week

Valuation
Technical
Day's Volume

CASH

16.82 k

Shareholding (Mar 2020)

FII

0.26%

Held by 1 FIIs

DII

99.74%

Held by 0 DIIs

Promoter

0.00%

iScoreScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

Dashboard

1

Poor Management Efficiency with a low ROE of 0%

  • The company has reported losses. Due to this company has reported negative ROE
2

Poor long term growth as Net Sales has grown by an annual rate of -26.13% and Operating profit at 9.04% over the last 5 years

 
3

The company has declared Negative results for the last 6 consecutive quarters

4

Risky -

stock-summaryMojo Parameters

Mojo Parameters

Stock DNA

stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

PLN 326 Million (Small Cap)

stock-summary
P/E

NA (Loss Making)

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

0.25

stock-summary
Return on Equity

-23.34%

stock-summary
Price to Book

4.95

Revenue and Profits:
Net Sales:
7 Million
(Quarterly Results - Mar 2025)
Net Profit:
-4 Million
stock-summaryTotal Returns
Total Returns (Price + Dividend) stock-summary
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
15.9%
0%
15.9%
6 Months
78.71%
0%
78.71%
1 Year
20.96%
0%
20.96%
2 Years
59.95%
0%
59.95%
3 Years
446.77%
0%
446.77%
4 Years
0.63%
0%
0.63%
5 Years
46.14%
0%
46.14%

Medicalgorithmics SA for the last several years.

Risk Adjusted Returns v/s stock-summary
stock-summaryNews & Corporate Actions

News

Icon
No Recent News for the Company

Announcements stock-summary

Icon
No announcement available

Corporate Actions stock-summary

Icon
No corporate action available
stock-summaryKey Factors

Quality key factors stock-summary

Factor
Value
Sales Growth (5y)
-26.13%
EBIT Growth (5y)
9.04%
EBIT to Interest (avg)
-17.34
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
0.03
Sales to Capital Employed (avg)
0.38
Tax Ratio
1.91%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
0.26%
ROCE (avg)
0.27%
ROE (avg)
0

Valuation key factors

Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
4.85
EV to EBIT
-20.83
EV to EBITDA
-23.65
EV to Capital Employed
4.25
EV to Sales
14.13
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
-20.41%
ROE (Latest)
-19.29%

Technicals key factors

Indicator
Weekly
Monthly
MACD
Mildly Bearish
Bullish
RSI
No Signal
Bearish
Bollinger Bands
Mildly Bearish
Mildly Bullish
Moving Averages
Mildly Bullish (Daily)
KST
Mildly Bullish
Bullish
Dow Theory
No Trend
Mildly Bullish
OBV
Mildly Bullish
No Trend
stock-summary Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
stock-summaryShareholding
Shareholding Snapshot : Mar 2020stock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Foreign Institutions

Domestic Funds

Held in 0 Schemes (0%)

Foreign Institutions

Held by 1 Foreign Institutions (0.26%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summaryFinancial
[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Mar'25 - QoQ",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "QoQ Growth in quarter ended Mar 2025 is 15.25% vs 13.46% in Dec 2024",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "QoQ Growth in quarter ended Mar 2025 is 8.70% vs -119.05% in Dec 2024",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Mar'25",
        "Dec'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "6.80",
          "val2": "5.90",
          "chgp": "15.25%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-3.60",
          "val2": "-4.90",
          "chgp": "26.53%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.30",
          "val2": "0.10",
          "chgp": "200.00%",
          "chgp_class": "negative"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-4.20",
          "val2": "-4.60",
          "chgp": "8.70%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-671.30%",
          "val2": "-891.90%",
          "chgp": "22.06%",
          "chgp_class": "positive"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2024 is -44.32% vs -31.26% in Dec 2023",
        "dir": -1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2024 is -2,583.33% vs -102.35% in Dec 2023",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Dec'24",
        "Dec'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "24.00",
          "val2": "43.10",
          "chgp": "-44.32%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-16.80",
          "val2": "2.50",
          "chgp": "-772.00%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "0.20",
          "val2": "0.10",
          "chgp": "100.00%",
          "chgp_class": "negative"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.70",
          "chgp": "-100.00%",
          "chgp_class": "negative"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-16.10",
          "val2": "-0.60",
          "chgp": "-2,583.33%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-852.60%",
          "val2": "3.20%",
          "chgp": "-85.58%",
          "chgp_class": "negative"
        }
      ]
    }
  }
]

Quarterly Results Snapshot (Consolidated) - Mar'25 - QoQstock-summary

Mar'25
Dec'24
Change(%)
Net Sales
6.80
5.90
15.25%
Operating Profit (PBDIT) excl Other Income
-3.60
-4.90
26.53%
Interest
0.30
0.10
200.00%
Exceptional Items
0.00
0.00
Consolidate Net Profit
-4.20
-4.60
8.70%
Operating Profit Margin (Excl OI)
-671.30%
-891.90%
22.06%
USD in Million.
Direction Arrows
Net Sales

QoQ Growth in quarter ended Mar 2025 is 15.25% vs 13.46% in Dec 2024

Direction Arrows
Consolidated Net Profit

QoQ Growth in quarter ended Mar 2025 is 8.70% vs -119.05% in Dec 2024

Annual Results Snapshot (Consolidated) - Dec'24stock-summary

Dec'24
Dec'23
Change(%)
Net Sales
24.00
43.10
-44.32%
Operating Profit (PBDIT) excl Other Income
-16.80
2.50
-772.00%
Interest
0.20
0.10
100.00%
Exceptional Items
0.00
0.70
-100.00%
Consolidate Net Profit
-16.10
-0.60
-2,583.33%
Operating Profit Margin (Excl OI)
-852.60%
3.20%
-85.58%
USD in Million.
Direction Arrows
Net Sales

YoY Growth in year ended Dec 2024 is -44.32% vs -31.26% in Dec 2023

Direction Arrows
Consolidated Net Profit

YoY Growth in year ended Dec 2024 is -2,583.33% vs -102.35% in Dec 2023

stock-summaryCompany CV
About Medicalgorithmics SA stock-summary
stock-summary
Medicalgorithmics SA
Pharmaceuticals & Biotechnology
Medicalgorithmics SA is a Poland-based company engaged in the advanced medical equipment and technology industry. The Company develops and manufactures system for the diagnosis of heart arrhythmia. Its product, named PocketECG, is used for remote monitoring of cardiac disorders, arrhythmia diagnosis and monitoring of heart, as well as is used for clinical drugs trials for cardiac safety. In addition, Medicalgorithmics SA provides services in the field of information technology and biotechnology, scientific research and development of natural sciences. Moreover, the Company works on the several projects, such as a device for tele-rehabilitation cardiology, software for optimizing repetitive task in hospitals, as well as devices and systems for remote description of the electrocardiography (ECG). It operates through MEDICALGORITHMICS US HOLDING CORPORATION and Medi-Lynx Cardiac Monitoring LLC and Medi-Lynx Cardiac Monitoring LLC.
Company Coordinates stock-summary
Company Details
Al. Jerozolimskie 81 , WARSZAWA None : 02-001
stock-summary
Tel: 48 22 825124948 697 613020
stock-summary
Registrar Details